# US 2013/0274127 A1 · Gene expression markers for prediction of response to phosphoinositide 3-kinase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0274127 A1
- Document ID: US20130274127A1
- Status: Published application
- Kind: A1
- Application number: 13/804,351
- Filed: 2013-03-14
- Published: 2013-10-17
- Earliest claimed: 2012-04-17
- Assignees: Genomic Health, Inc.
- Applicants: Genomic Health, Inc.
- Inventors: Joffre B. Baker; Robert J. Pelham; Kevin A. Kwei
- Web page: https://patentgrep.com/patent/US20130274127A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5758: {involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites}
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides methods for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor. The methods generally involve determining an expression level of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor. The present invention also provides methods for increasing sensitivity of a tumor cell to a PI3K inhibitor by contacting the tumor cell with an activator or inhibitor of a gene product that correlates with sensitivity or resistance to a PI3K inhibitor.

## Claims

### Claim 1

A method for predicting a likelihood that a tumor cell will be sensitive or resistant to a phosphoinositide 3-kinase (PI3K) inhibitor, comprising:
a. assaying an expression level of one or more genes selected from Table 2 or Table 3 in a tumor cell; and
b. predicting a likelihood that the tumor cell will be sensitive to the PI3K inhibitor, wherein increased expression level of the one or more genes selected from Table 2 compared to the expression level of the one or more genes selected from Table 2 in a PI3K inhibitor-resistant tumor cell is positively correlated with a likelihood that the tumor cell will be sensitive to the PI3K inhibitor, or predicting a likelihood that the tumor cell will be resistant to the PI3K inhibitor, wherein increased expression level of the one or more genes selected from Table 3 compared to the expression level of the one or more genes selected from Table 3 in a PI3K inhibitor-susceptible tumor cell is positively correlated with a likelihood that the tumor cell will be resistant to the PI3K inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the one or more genes selected from Table 2 is selected from VAV3, DGKE, MBD1, SERP1, TXNL1, NLGN4X, C1ORF91, SLC25A1, ZBTB40, FAM51A1, LOC116349, KIAA1468, PIGN, PKD1L1, SELT, CISH, MGC50559, NPY5R, PEX10, and C6ORF35.

### Claim 3 (depends on 1)

The method of claim 1, further comprising increasing the sensitivity of the tumor cell to the PI3K inhibitor, comprising, contacting the tumor cell with an activator of the one or more genes selected from Table 2, and contacting the tumor cell with a PI3K inhibitor.

### Claim 4

(canceled)

### Claim 5

The method of claim [[4]] 1, wherein the one or more genes selected from Table 3 is selected from TRIM50C, GALR2, INSL3, LOC389633, GTPBP10, PGRMC1, DNASE1L3, CACNG2, FAM90A1, OGT, FKBP6, GDAP1L1, CHRNB1, NLGN3, ZNF259, DDN, NXF3, MGC35366, TANK, and LOC116123.

### Claim 6 (depends on 1)

The method of claim 1, further comprising increasing the sensitivity of the tumor cell to the PI3K inhibitor, comprising, contacting the tumor cell with an inhibitor of the one or more genes selected from Table 3, and contacting the tumor cell with the PI3K inhibitor.

### Claim 7 (depends on 1)

The method of claim 1, wherein the expression level of the one or more genes selected from Table 2 or Table 3 is normalized against an expression level of one or more reference genes to obtain a normalized expression level of the one or more genes selected from Table 2 or Table 3.

### Claim 8 (depends on 1)

The method of claim 1, wherein the expression level of the one or more genes selected from Table 2 or Table 3 is a level of RNA transcript of the one or more genes selected from Table 2 or Table 3.

### Claim 9

The method of, wherein the expression level of the one or more genes selected from Table 2 or Table 3 is a polypeptide level of the one or more genes selected from Table 2 or Table 3.

### Claim 10 (depends on 8)

The method of claim 8, wherein the level of RNA transcript of the one or more genes selected from Table 2 or Table 3 is assayed using reverse transcription polymerase chain reaction (RT-PCR).

### Claim 11 (depends on 1)

The method of claim 1, wherein the tumor cell is from a biopsy sample.

### Claim 12 (depends on 1)

The method of claim 1, wherein the tumor cell is from a fixed, wax-embedded tissue sample.

### Claim 13 (depends on 1)

The method of claim 1, further comprising creating a report based on the normalized expression level of the one or more genes selected from Table 2 or Table 3.

### Claim 14

A method of increasing sensitivity of a tumor cell to a PI3K inhibitor, comprising,
contacting the tumor cell with an inhibitor of one or more genes selected from Table 3; and
contacting the tumor cell with a PI3K inhibitor.

### Claim 15

A method of increasing sensitivity of a tumor cell to a PI3K inhibitor, comprising,
contacting the tumor cell with an activator of one or more genes selected from Table 2; and
contacting the tumor cell with a PI3K inhibitor.

### Claim 16 (depends on 1)

The method of claim 1, wherein the tumor cell is selected from a breast, colon, NSCLC, renal, ovarian, prostate, and melanoma tumor cell.

### Claim 17 (depends on 1)

The method of claim 1, wherein the PI3K inhibitor is GDC-0941.
